Money20/20 Launches The Money Awards, the New Global Fintech Awards and Unveils Prestigious Jury President Line-Up
2.4.2025 14:10:00 CEST | Business Wire | Press release
The premier benchmark for fintech excellence recognizes transformative innovation with winners unveiled at Money20/20 USA in October 2025
www.money2020.com, the world’s leading fintech show and the place where money does business, today announces the launch of The Money Awards, a premier global awards program recognizing transformative innovation across the financial technology ecosystem. Celebrating companies and leaders shaping the future of money, the money awardssets a new global benchmark for excellence in fintech.
Backed by a rigorous, merit-based judging process and a globally diverse panel of industry leaders, The Money Awards will recognize companies that are redefining industries, pushing the boundaries of technology, and setting new standards for product quality and innovation.
“The Money Awards are more than an awards program—they are a platform to showcase those leading the fintech revolution and will become the ultimate benchmark for innovation and impact in financial services,” said Scarlett Sieber, Money20/20’s Chief Strategy and Growth Officer. “Winning a Money award is a powerful catalyst for growth, investment, and global validation.”
The program features five awards: Startup, Banking, Payments, Partnerships & Strategic Alliance, and the Diamond Award. Each Award will be led by a distinguished Jury President, including Joanne Hannaford, CIO & CPO Corporate Bank of Deutsche Bank (Banking), Lynn Martin, President of NYSE Group (Diamond), Anthony Thomas, MD, FinTech at Delivery Hero (Partnerships & Strategic Alliance), Howard R. Fields, Chief Ethics & Compliance Officer at Mastercard (Payments), and Chetan Puttagunta, General Partner at Benchmark (Startup).
“I’m thrilled to serve as a Jury President for the inaugural Money20/20 Awards, recognizing the companies shaping the future of financial services,” said Lynn Martin, President of the New York Stock Exchange. “As the listing venue where big ideas come to life, the NYSE looks forward to celebrating the next generation of visionaries redefining the industry and setting the pace for global innovation.”
The Money Awards will be judged by an independent panel of globally respected leaders, with deep expertise and background in fintech, banking, payments, and technology. Jurors will evaluate submissions through a transparent and impartial process that includes online reviews followed by in-person deliberations at Money20/20 USA in October 2025.
“As a Jury President for the Money Awards, I’m honored to recognize the most prestigious global achievements in fintech,” said Joanne Hannaford, CIO & CPO Corporate Bank, Deutsche Bank. “A global fintech award not only celebrates outstanding accomplishments in our industry but also raises the bar for excellence, fosters innovation, and inspires the next generation of fintech leaders. I look forward to celebrating the groundbreaking companies and leaders redefining the future of financial technology.”
“I am honored and thrilled to be selected as a Jury President for the prestigious Money20/20 Payments Award,” said Howard R. Fields, Chief Ethics & Compliance Officer, Mastercard. “This award represents the pinnacle of innovation in the payments industry, recognizing groundbreaking ideas that shape the future of financial technology. I look forward to engaging with the brightest minds in the field and celebrating the transformative advancements that will define the next era of payments.”
The awards will culminate in the announcement of the inaugural Money Awards Trophy winners at Money20/20 USA, with further celebrations planned for Money20/20 Europe and Asia, ensuring global recognition for winning companies. Winners will receive a bespoke trophy and benefit from year-round visibility through Money20/20’s platforms, including exclusive speaking opportunities, media exposure, investor visibility, and networking at Money20/20 shows worldwide.
“I’m thrilled to serve as Jury President for this year’s Money20/20 Awards for Startups,” said Chetan Puttagunta. “Money20/20 has long been an important global platform for recognizing fintech innovation and propelling the industry forward. As an investor focused on early-stage startups, I'm particularly excited about the Startup Award—not only to elevate individual companies and entrepreneurs but also to create further collaboration in the ecosystem to drive the next generation of financial technology.”
Anthony Thomas, MD, FinTech at Delivery Hero, commented: “I'm excited to be a part of the Money20/20 Awards as Partnerships & Strategic Alliance Jury President. The fintech landscape thrives on collaboration, and I look forward to recognizing the companies and leaders who are forging impactful partnerships and shaping the future of financial services.”
Entries for jury applications are now open. For more information on categories, judging criteria, and how to enter, visit www.money2020.com/awards.
About Money20/20
Launched by industry insiders in 2012, Money20/20 has rapidly become the heartbeat of the global fintech ecosystem. Over the last decade, the most innovative, fast-moving ideas and companies have driven their growth on our platform. Mastercard, Wise, J.P. Morgan, SHIELD, Convera, Stripe, Google, VISA, Adyen, and more make transformational deals and raise their global profile with us. Money20/20 attracts leaders from the world’s greatest banks, payments companies, VC firms, regulators and media platforms: convening to cut industry-shaping deals, build world-changing partnerships and unlock future-defining opportunities in Bangkok (22-24 April 2025)in Amsterdam (3-5 June 2025), in Riyadh ( 15-17 September 2025), and in Las Vegas (26-29 October 2025). Money20/20 is where the world’s fintech leaders convene to grow their businesses. Money20/20 is part of Ascential plc. Follow Money20/20 on X and LinkedIn for show developments and updates. We’re Where Money Does Business. Follow Money20/20 on X for show developments and updates. You can also find us on LinkedIn at Money20/20.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402656688/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom